Pharmacogenetic Analysis of Variants in IL-6 Signaling and Response to Modern Therapeutic Approaches in Greek Patients with Atopic Dermatitis.

doi:10.3390/genes17050575

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pharmacogenetic Analysis of Variants in IL-6 Signaling and Response to Modern Therapeutic Approaches in Greek Patients with Atopic Dermatitis.

Genes - 18 May 2026

Triantafillidi Dimitra, Tziouvara Vasiliki, Pontikas Alexandros, Akritidis Adam, Antonatos Charalabos, Zacharopoulou Aikaterini, Tsiogka Aikaterini, Kleidona Ileana-Afroditi, Grafanaki Katerina, Chrysospathi Alexandra, Ntavari Niki, Kampra Elli, Georgiou Sophia, Zafiriou Efterpi, Gregoriou Stamatis, Vasilopoulos Yiannis

Abstract excerpt

BACKGROUND/OBJECTIVES: We conducted the first pharmacogenetic investigation of atopic dermatitis in a cohort of 43 Greek patients, focusing on key variants within the IL6/JAK/STAT signaling axis, a pathway central to inflammation and therapeutic targeting. METHODS: Patients receiving dupilumab, JAK inhibitors, or topical corticosteroids were prospectively evaluated, with treatment response assessed by changes in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dermatitis, Atopic

Share to Greece

Share to Interleukin-6

Share to Janus Kinase 1

Share to Pharmacogenetics

Share to Pharmacogenomic Testing

Share to Receptors, Interleukin-6

Source

Open in PubMed Open full text

Identifiers

PMID: 42195032
DOI: 10.3390/genes17050575
PMCID: PMC13205716

Genes

IL6
IL6R
JAK1
TRAF3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic Analysis of Variants in IL-6 Signaling and Response to Modern Therapeutic Approaches in Greek Patients with Atopic Dermatitis.PMID 42195032Read ↗

Human germline heterozygous gain-of-function <i>STAT6</i> variants cause severe allergic diseaseSemantic proximity Read ↗

Genetic profiling of patients with atopic dermatitis reveals immune and skin barrier variants associated with generalized eczema and optimal response to Dupilumab therapy.Semantic proximity Read ↗

Genetic landscape of atopic dermatitis.Semantic proximity Read ↗

A functional IL-6 receptor (IL6R) variant is a risk factor for persistent atopic dermatitis.Semantic proximity Read ↗

Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.Semantic proximity Read ↗

A De Novo STAT6 p.D419G Variant Causing Severe Multi-Organ Allergic Disease: Case Report on a Transformative Response with DupilumabSemantic proximity Read ↗

Genetically proxied IL-6 receptor inhibition is associated with increased risk of atopic dermatitis.Semantic proximity Read ↗

Differential Associations of Interleukin 6 Receptor Variant Across Genetic Ancestries and Implications for Targeted TherapiesSemantic proximity Read ↗

Protein-coding variants contribute to the risk of atopic dermatitis and skin-specific gene expression.Semantic proximity Read ↗

A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-α and Anti-IL-12/23 Agents.Semantic proximity Read ↗

Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe PsoriasisSemantic proximity Read ↗

Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.